Immix Biopharma Investor Presentation Deck
Outpatient Access To NXC-201 Potentially Increases CAR-T Addressable Market by 10-20x
Today -
CAR-T
Treatment
Options
NXC-201
Treatment
Options
I
I Today: CAR-T is accessible at only 5%
I of US hospitals, mostly academic
I research centers in major cities
L
CLINIC
00
CLINIC
I
****
I
I
+ HOSPITAL
884
CLINIC
+HOSPITAL
884
Future: NXC-201 potentially accessible at many more US hospitals,
academic research centers in cities + regional medical centers and clinics
--
■
CLINIC
00
1000
+ HOSPITAL
+884
CLINIC
01
+HOSPITAL
884
I I
I
I
CLINIC
+ HOSPITAL
188
BA
CLINIC
+HOSPITAL
■
CLINIC
I
■
000
●●●
IMMIX
So BIOPHARMA
+884
+ HOSPITAL
CLINIC
0
+HOSPITAL
88k
CLINIC
■
Source: Sharma A, et al, Epidemiology and Predictors of 30-Day Readmission in CAR-T Cell Therapy Recipients. Transplant Cell Ther. 2023 Feb;29(2):108.e1-108.e7. doi: 10.1016/j.jtct.2022.11.004. Epub 2022 Nov 9. PMID: 36371048. George Washington University "The
Differences Between Academic and Community Medical Centers"View entire presentation